US Edition
Quia Timet Action Succeeds In Patent Dispute Over Biosimilar Of Nivolumab
Summary by lexorbis.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Quia Timet Action Succeeds In Patent Dispute Over Biosimilar Of Nivolumab
While disposing of I.A. 10533/2024 for injunction in a patent infringement dispute over a biosimilar of Nivolumab between E. R. Squibb and Sons, LLC & Ors. vs Zydus Lifesciences Limited [CS(COMM) 376/2024], the Delhi High Court issued a preliminary injunction order on July 18, 2025, restraining Zydus Lifesciences from launching its nivolumab biosimilar (ZRCr-4276). This order came as a quia timet action in view of the alleged “receipt of informa…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
